Dogwood Therapeutics is a pre-revenue biopharmaceutical company focused on its Na v 1.7 program Halneuron and antiviral combinations; after the October 2024 Combination the company reports total assets of $96.7M including capitalized IPR&D of $69.3M and goodwill of $12.46M. Cash totaled $13.40M at June 30, 2025 and net cash used in operating activities was $8.71M for the six months.
Dogwood recorded net losses of $3.81M for the quarter and $14.73M year-to-date, producing an accumulated deficit of $88.55M and basic/diluted net loss per common share of $(1.99) (quarter) and $(9.51) (six months). The company completed a registered direct offering (net proceeds ~$4.25M) and converted related-party debt into Series A-1 preferred (debt extinguishment of ~$19.9M with a recognized loss of $6.13M). Management discloses substantial doubt about the company’s ability to continue without additional financing beyond the first quarter of 2026.
Dogwood Therapeutics, Inc. furnished a press release reporting its results of operations for the quarter ended June 30, 2025, which is included as Exhibit 99.1 and is incorporated by reference into Item 2.02 of this Current Report.
The Form notes the information is being furnished, not filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings. The registrant identifies as an emerging growth company and did not check the box indicating an election to forgo the extended transition period. The company’s common stock trades on the Nasdaq Capital Market under ticker DWTX. The report is signed by Angela Walsh, Chief Financial Officer, Corporate Secretary and Treasurer.